Finding the health-care expenditure that drives variation in cancer survival
Menée à partir de données de 27 pays européens portant sur 890 730 patients atteints d'une tumeur lymphoïde diagnostiquée entre 2001 et 2013 (12 types de tumeurs), cette étude rétrospective estime la survie à 5 ans et à 10 ans et analyse les dépenses de santé nationales associées
EUROCARE 1 , 2 and other international comparison studies of cancer survival 3 , 4 provide essential evidence for reporting inequalities and monitoring population-level improvements. Research in this area continues to refute the long-standing criticisms 5 of the comparability of international survival data. Cancer survival is a key metric that reflects improvements in treatment and care for patients diagnosed with cancer (ie, trends in survival can closely map to the timing of treatment advances). Researchers should always critically reflect on whether data are sufficiently comparable, interpret survival trends in the context of changes in incidence or mortality rates, 6 and ensure analyses are stratified by key prognostic variables to isolate drivers of the differences. Initiatives to improve the recording and harmonisation of stage at diagnosis in cancer registration 7 are crucial for this endeavour
The Lancet Oncology 2023